Your Health Matters.
OTHER PRODUCT CANDIDATES
Regend Therapeutics is advancing a diversified pipeline beyond the core programs, leveraging scalable platforms to develop regenerative therapies across lung, kidney, and age-related diseases.
Our pipeline spans preclinical research, IND-enabling studies, investigator-initiated trials, and clinical-stage programs, integrating autologous and allogeneic cell therapies as well as next-generation biologics.
Expanding Lung and Kidney Regeneration
REGEND002 is a next-generation rejuvenated lung progenitor cell product, which is based on our unique chemical partial reprogramming technical platform to reverse biological ages of old, unhealthy autologous cells, aiming to expand our target population and improve therapeutic efficacy to a new level.
REGEND007 is an allogeneic cell therapeutic product candidate based on off-the-shelf human lung progenitor cells, offers significant advantages in accessibility, treatment timeliness, and cost.
REGEND008 is has the potential to be a promising universal kidney progenitor cell therapeutic product for the treatment of CKD, with potential to improve renal function and delay disease progression.
Targeting Multi-Organ Aging-Associated Diseases
REJUVE101 is an engineered extracellular vesicle-based therapy designed to deliver and enhance the expression of an anti-aging gene promising for the treatment of age-related diseases affecting organ systems.
REJUVE109 is comprised of engineered extracellular vesicle carrying reprogramming chemicals capable of epigenetically reversing cellular aging phenotypes in stem cell systems.
A Platform-Driven Company
Our pipeline integrates multiple regenerative modalities, including cell therapies, rejuvenation technologies, and biologics. Together, these programs position Regend Therapeutics as a platform-driven company with the potential to deliver innovative therapies across multiple indications.
Our integrated technology platform, particularly the R-Clone epithelial stem cell cloning platform, enables standardized product development and facilitates rapid expansion into new organ systems beyond lung and kidney.